Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday

Precision BioSciences (NASDAQ:DTIL) is anticipated to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $9.0750 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Precision BioSciences Stock Performance

Shares of DTIL opened at $6.02 on Monday. The company has a current ratio of 13.32, a quick ratio of 13.32 and a debt-to-equity ratio of 0.24. The firm’s fifty day simple moving average is $4.67 and its two-hundred day simple moving average is $5.10. Precision BioSciences has a 12 month low of $3.53 and a 12 month high of $8.82. The stock has a market capitalization of $148.87 million, a P/E ratio of -1.17 and a beta of 1.28.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. Wall Street Zen upgraded Precision BioSciences from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $19.00 price target on shares of Precision BioSciences in a research note on Friday, March 13th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Precision BioSciences currently has a consensus rating of “Hold” and an average target price of $39.50.

Insider Activity

In related news, CEO Michael Amoroso sold 20,559 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $78,946.56. Following the completion of the sale, the chief executive officer directly owned 243,392 shares of the company’s stock, valued at $934,625.28. The trade was a 7.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider J. Jefferson Smith sold 10,200 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $4.03, for a total value of $41,106.00. Following the completion of the transaction, the insider owned 110,184 shares in the company, valued at approximately $444,041.52. The trade was a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 93,845 shares of company stock worth $376,677 in the last three months. Company insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Precision BioSciences

Large investors have recently modified their holdings of the company. Commonwealth Equity Services LLC grew its holdings in shares of Precision BioSciences by 67.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 93,306 shares of the company’s stock valued at $388,000 after buying an additional 37,461 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Precision BioSciences in the 4th quarter worth about $295,000. Quarry LP raised its holdings in shares of Precision BioSciences by 15.1% in the 4th quarter. Quarry LP now owns 68,311 shares of the company’s stock worth $284,000 after acquiring an additional 8,936 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in Precision BioSciences in the 2nd quarter valued at about $260,000. Finally, Quadrature Capital Ltd lifted its position in Precision BioSciences by 344.7% in the 4th quarter. Quadrature Capital Ltd now owns 62,129 shares of the company’s stock valued at $258,000 after acquiring an additional 48,158 shares in the last quarter. 37.99% of the stock is currently owned by institutional investors.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.